{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Post-surgical+Ocular+Inflammation&page=2",
    "query": {
      "condition": "Post-surgical Ocular Inflammation",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 40,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Post-surgical+Ocular+Inflammation&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Post-surgical+Ocular+Inflammation&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T14:30:01.245Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00333255",
      "title": "Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Nepafenac Ophthalmic Suspension, 0.1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 267,
      "start_date": "2005-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-07-08",
      "last_synced_at": "2026-10-01T14:30:01.245Z",
      "location_count": 1,
      "location_summary": "Nacogdoches, Texas",
      "locations": [
        {
          "city": "Nacogdoches",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00333255"
    },
    {
      "nct_id": "NCT00366691",
      "title": "Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cataract Extraction"
      ],
      "interventions": [
        {
          "name": "Acular LS",
          "type": "DRUG"
        },
        {
          "name": "Lotemax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2006-02",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2018-06-14",
      "last_synced_at": "2026-10-01T14:30:01.245Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00366691"
    },
    {
      "nct_id": "NCT04396990",
      "title": "The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospective Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Refractive Surgery"
      ],
      "interventions": [
        {
          "name": "Dextenza 0.4Mg Ophthalmic Insert",
          "type": "DRUG"
        },
        {
          "name": "Topical Prednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vance Thompson Vision",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2020-06-08",
      "completion_date": "2020-09-28",
      "has_results": true,
      "last_update_posted_date": "2024-07-30",
      "last_synced_at": "2026-10-01T14:30:01.245Z",
      "location_count": 1,
      "location_summary": "Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04396990"
    },
    {
      "nct_id": "NCT02508337",
      "title": "Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Inflammation",
        "Pain",
        "Cataract"
      ],
      "interventions": [
        {
          "name": "XG-102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xigen SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 309,
      "start_date": "2015-07",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2017-01-24",
      "last_synced_at": "2026-10-01T14:30:01.245Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02508337"
    },
    {
      "nct_id": "NCT04316936",
      "title": "Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cataract Surgery"
      ],
      "interventions": [
        {
          "name": "Omidria",
          "type": "DRUG"
        },
        {
          "name": "Dextenza (dexamethasone ophthalmic insert) 0.4mg",
          "type": "DRUG"
        },
        {
          "name": "Dexycu, 9% Intraocular Suspension",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone Acetate 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Silverstein Eye Centers",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 15,
      "start_date": "2019-12-10",
      "completion_date": "2020-12-23",
      "has_results": false,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-10-01T14:30:01.245Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04316936"
    },
    {
      "nct_id": "NCT01109173",
      "title": "Confirmatory Study Nepafenac 0.3%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Nepafenac Ophthalmic Suspension, 0.3%",
          "type": "DRUG"
        },
        {
          "name": "Nepafenac Ophthalmic Suspension, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Nepafenac Ophthalmic Suspension 0.3% Vehicle",
          "type": "OTHER"
        },
        {
          "name": "NEVANAC Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2120,
      "start_date": "2010-06",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2012-11-30",
      "last_synced_at": "2026-10-01T14:30:01.245Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01109173"
    },
    {
      "nct_id": "NCT03496467",
      "title": "Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pain",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "Nepafenac PPDS",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo PPDS",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Mati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "22 Years to 99 Years"
      },
      "enrollment_count": 56,
      "start_date": "2018-03-05",
      "completion_date": "2018-12-17",
      "has_results": true,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-10-01T14:30:01.245Z",
      "location_count": 3,
      "location_summary": "Edgewood, Kentucky • Garden City, New York • Mt. Pleasant, South Carolina",
      "locations": [
        {
          "city": "Edgewood",
          "state": "Kentucky"
        },
        {
          "city": "Garden City",
          "state": "New York"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03496467"
    },
    {
      "nct_id": "NCT04781335",
      "title": "\"A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation\"",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Dexycu",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care post operative eye drops (steroid, antibiotic, NSAID)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Eye Institute of West Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 25,
      "start_date": "2020-02-20",
      "completion_date": "2022-12-22",
      "has_results": false,
      "last_update_posted_date": "2025-02-25",
      "last_synced_at": "2026-10-01T14:30:01.245Z",
      "location_count": 1,
      "location_summary": "Largo, Florida",
      "locations": [
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04781335"
    },
    {
      "nct_id": "NCT01847638",
      "title": "Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cataract",
        "Retinal Edema",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "Prolensa (bromfenac 0.07%)",
          "type": "DRUG"
        },
        {
          "name": "Ilevro (nepafenac 0.3%)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melissa Toyos",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2013-04-01",
      "completion_date": "2018-08-23",
      "has_results": true,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-10-01T14:30:01.245Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01847638"
    },
    {
      "nct_id": "NCT05665270",
      "title": "A Study for Post op Inflammation After Cataract Surgery",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Dextenza 0.4Mg Ophthalmic Insert",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone Acetate 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyse Eyecare",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2023-01-30",
      "completion_date": "2023-12-15",
      "has_results": false,
      "last_update_posted_date": "2023-04-26",
      "last_synced_at": "2026-10-01T14:30:01.245Z",
      "location_count": 1,
      "location_summary": "Northbrook, Illinois",
      "locations": [
        {
          "city": "Northbrook",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05665270"
    }
  ]
}